IMPORTANCE Guidelines recommend using gabapentin to decrease postoperative pain and opioid use, but significant variation exists in clinical practice.
O ver 51 million Americans undergo surgery annually, and the majority are prescribed opioids for pain management. 1, 2 Up to 13% of patients initiate chronic opioid use after surgery. 3, 4 Most patients undergoing surgery require opioids regardless of prior opioid-related adverse events, and patients receiving opioids prior to surgery require higher doses over extended periods, compounding the risks of chronic opioid use, misuse, addiction, and overdose. [5] [6] [7] [8] [9] [10] Medicine is facing the challenge of adequately managing pain while limiting opioid consumption. One approach is the concomitant use of nonopioid adjuvants for pain relief. Gabapentin is a ligand of the α2δ subunit of voltage-dependent calcium channels attenuating calcium channel influx, thereby decreasing excitatory transmitter release and spinal sensitization.
11 Gabapentin may also activate the descending noradrenergic pain inhibitory system and decrease microglial activation as well as the expression of proinflammatory cytokines.
11
Perioperative gabapentin may reduce the incidence and intensity of postoperative pain up to 6 months after otolaryngology, orthopedic, mastectomy, and abdominal/ pelvic operations.
12-15 Professional guidelines advocate for perioperative administration of gabapentin as a component of multimodal analgesia, 16 but its efficacy in the context of multimodal analgesia has been mixed, and usual care varies across operations and hospitals nationwide.
17-21
Conclusions regarding gabapentin's effect on chronic postsurgical pain have been limited by studies with small sample sizes, limited postoperative follow-up, patient attrition, diverse surgical cohorts, and variable dosing regimens. 18, 20, 22, 23 Given evidence of reduced opioid requirements, professional societies recommend the use of gabapentin for optimal acute pain mangement. 16 However, a recent meta-analysis found a negligible reduction of 24-hour morphine consumption. 24 These findings were limited by low-quality evidence due to small study sizes and inconsistency highlighting the need for fully powered randomized clinical trials. 24 Our goal was to examine remote postoperative pain and opioid use with extended follow-up accounting for the natural waxing and waning course of pain and opioid use rather than arbitrarily defining end points of acute, subacute, or chronic pain. Furthermore, prior work emphasizes that the determinants of postoperative pain resolution and opioid cessation are distinct, 25 ,26 necessitating separate analysis of gabapentin's efficacy on these outcomes. The primary objective of this trial was to investigate, among adults aged 18 to 75 years undergoing surgery, whether 10 doses of perioperative gabapentin over 72 hours compared with placebo increased the rate of pain cessation after surgery in a double-blind randomized clinical trial with up to 2 years of longitudinal follow-up. To determine the effect of perioperative gabapentin on postoperative opioid use, our prespecified secondary outcome was the rate of opioid cessation after surgery. room pharmacy. One log sheet was generated per combination of surgeon/surgery. The pharmacist documented the patient's information on a randomization card that was placed in a sealed envelope indicating which medication was prescribed. Participants, clinicians, and researchers were blinded to allocation until completion of statistical analyses. The placebo group received 1 capsule of active placebo (lorazepam, 0.5 mg) and 3 capsules of inactive placebo preoperatively, followed by 2 capsules of inactive placebo 3 times a day starting on postoperative day 1 and continued for 72 hours (10 total doses). Lorazepam was chosen as the active placebo to match the sedating effects of preoperative gabapentin. Postoperatively, active placebo was considered unnecessary since most patients received other analgesic medications. The treatment group received 4 capsules of gabapentin, 300 mg (1200 mg total), preoperatively and 2 capsules of gabapentin, 300 mg, 3 times a day (600 mg 3 times a day) postoperatively (10 total doses). Physicians not part of the research team were precluded from prescribing gabapentin or pregabalin.
Participants experiencing significant sedation or dizziness (≥7 of 10 adverse effect severity rating) had subsequent doses of study drug reduced by half (1 capsule). If participant dizziness or sedation remained at a severity level of 7 or more of 10 possible levels at the next assessment, medication administration was discontinued.
Assessments
Prior to surgery, participants completed a presurgical questionnaire packet assessing pain and opioid use with the Brief Pain Inventory. 28 Patients completed the Brief Pain Inventory twice, with the first referencing pain at the upcoming surgical site and the second referencing pain elsewhere. Participants reported on author-generated measures of selfreported likelihood of developing chronic pain after surgery, self-perceived sensitivity to pain, and self-perceived likelihood of addiction to pain medication after surgery (eAppendix1inSupplement 2). 25 The Opioid Risk Tool was administered to identify patients at risk for opioid-related aberrant behaviors (score range, 0-26, with 0-3 indicating low risk).
29
Other assessment tools included the Marlow-Crowne Social Desirability Scale (score range, 0-33, with 0-8 indicating low concern for social approval and 20-33 indicating high concern for social approval), 30 Barratt Impulsivity Scale (score range, 30-120, with higher scores representing greater 33 Euroqol Visual Analog Scale (score range for self-assessment of health, 0-100, with 0 representing the worst imaginable health state and 100 representing the best imaginable health state), 34 and the Dizziness or Sedation Scale (11-point numeric rating scales: 0 indicates no sedation and 10, worst sedation imaginable; 0 indicates no dizziness and 10, worst dizziness imaginable; subjective ratings by patients).
35
After surgery, investigators assessed adverse effects daily while patients were receiving study medication. The participants were asked about the presence and severity of listed and additional adverse effects. To assess blinding, the patients were asked whether they believed they had received placebo or gabapentin on each postoperative day that the study drug was administered.
After discharge, a modified Brief Pain Inventory was administered over the telephone to assess pain related to the surgical site, medication use, and pain interference (eAppendix 1inSupplement 2). Calls continued until patients had 5 consecutive reports of 0 of 10 average pain levels at their surgical site, 5 consecutive reports of no opioid use, and patientdefined full recovery. Call frequency was daily for 3 months, weekly thereafter up to 6 months, and monthly thereafter up to 2 years after surgery.
Study Outcomes
The primary outcome was time to pain resolution (5 consecutive reports of 0 of 10 levels of average pain at the surgical site on the numeric rating scale of pain). Secondary outcomes were time to opioid cessation (5 consecutive reports of no opioid use) and the proportion of participants with continued pain or opioid use at 6 months and 1 year.
Statistical Analysis
The study was designed to have 90% power to detect a favorable hazard ratio (HR) for an increased time to pain cessation of 1.33 in the gabapentin group compared with the placebo group. With a total 2-sided type I error rate of 0.05, 560 patients had to be enrolled, assuming at least 504 pain cessation events (with a 10% censoring rate based on previous data). Interim analysis was planned following every 100 pain cessation events with a partitioned α level to maintain the overall study α at .05.
Statistical analyses were performed with SAS software, version 9.4 (SAS Institute Inc). All statistical tests were 2-tailed. Continuous variables were compared with the t test and cat- c These events involved postoperative hemodynamic instability, and a hematoma at the surgical site in patients randomized to placebo, and pulmonary embolism and pneumothorax in those randomized to gabapentin.
d Eleven-point numeric rating scales were used (0, no sedation and 10, worst sedation imaginable; 0, no dizziness and 10, worst dizziness imaginable; subjective rating by patients).
egorical data were compared with the χ 2 test. Time to pain and opioid cessation were analyzed in the intention-to-treat (ITT) population with the HR and 2-sided 95% CIs based on a Cox proportional hazards model stratified by surgery type as prespecified in our analytic plan. Stratification controlled for the different degrees of tissue healing associated with each type of surgery and the associated multimodal analgesia protocols of specific operations (eg, total hip or knee replacement). 25 Stratification also controlled for the varying risk of persistent postsurgical pain across different operations. A separate prespecified perprotocol analysis of participants who received all study drug doses was conducted in a similar manner. Continued pain and opioid use at 6 and 12 months was analyzed in the ITT population with the odds ratio based on logistic regression accounting for stratification by surgery type. Prespecified subgroup analyses included high-risk subgroups defined by the presence of posttraumatic stress disorder, depression, and high self-report of addiction susceptibility. Additional post hoc subgroup analyses included surgery type, elevated state and trait anxiety inventory scores, and elevated Opioid Risk Tool scores. All analyses were completed before the data were unblinded. Subgroup analyses were conducted for surgery type and at-risk participant groups based on preoperative assessments (eAppendix 2 in Supplement 2). Adverse events were summarized for all patients who received at least 1 dose of study drug.
Results

Patients
A total of 1805 patients were screened for eligibility between May 25, 2010, and July 25, 2014. Of the 1383 patients who did not meet inclusion criteria, most exceeded the upper age limit or did not speak English (Figure) . Four hundred twenty-two patients underwent randomization, with 215 assigned to receive gabapentin and 207 assigned to receive active placebo ( Figure) . Treatment was initiated in 208 patients randomized to gabapentin and 203 patients randomized to placebo with at least 1 day of follow-up data in 208 patients receiving gabapentin and 202 patients receiving placebo (ITT and safety analysis population). Of patients included in the ITT analysis, mean (SD) age was 56.7 (11.7) years; 256 (62.4%) were women and 154 (37.6%) were men. A total of 139 (66.8%) patients received the complete protocol of perioperative gabapentin and 146 (71.9%) patients received the complete protocol of active placebo (per-protocol population). Overall, 125 of 410 patients (30.5%) did not receive the full protocol of study drug; 56 of 202 patients (27.7%) randomized to placebo and 69 of 208 patients (33.2%) randomized to gabapentin received a partial dose with no significant difference in the proportions between the groups (P = .23). Overall, 94 of 410 patients (22.9%) reported increased dizziness or sedation ( Table 1) . Baseline sociodemographic characteristics and intraoperative management were comparable ( Table 2) . Preoperative pain was similar between the groups. The 2 groups were also similar across author-generated measures of selfperceived likelihood of developing chronic pain after surgery, sensitivity to pain, and likelihood of addiction to pain medication after surgery. No differences were noted in pre- However, participants receiving gabapentin had a 24% increase in the rate of opioid cessation after surgery (HR, 1.24; 95% CI, 1.00-1.54; P = .05) as reported in Table 3 . Median time to opioid cessation was 25 days (IQR, 8-53 days) in patients receiving gabapentin and 32 days (IQR, 9-55 days) in patients receiving active placebo. Opioid cessation rates by time intervals are presented in Table 4 . Eighty-two percent of participants were still receiving opioids 5 days after surgery. Median times to opioid cessation within each surgery type are reported in Table 4 . In the per-protocol analysis, perioperative gabapentin similarly had no effect on pain cessation, but resulted in a 37% increase in the rate of opioid cessation after surgery (HR, 1.37; 95% CI, 1.06-1.88; P = .02). None of the additional secondary analyses was significant (Table 3) . Preplanned subgroup analyses were completed for time to opioid and pain cessation with no significant heterogeneity of treatment effects demonstrated except for surgery type (eFigure 1 and eFigure 2 in Supplement 2).
Adverse Events
There was no significant difference in the rate of 1 or more reported adverse events between groups (Table 1) , which occurred in 191 of 202 (94.6%) patients receiving placebo and 195 of 208 (93.8%) receiving gabapentin (P = .70). No significant difference was noted in the proportion of patients who did not receive the full protocol of gabapentin or placebo owing to significant sedation or dizziness (P = .23). Patients receiving gabapentin reported less constipation than those receiving active placebo (61.5% vs 72.8%; P = .02) as well as more impaired coordination (42.3% vs 32.7%; P = .03) and rash (13.0% vs 6.9%; P = .04).
Serious adverse events were rare, occurring in 2 patients in each group. These events involved postoperative hemodynamic instability and a hematoma at the surgical site in patients randomized to placebo, and pulmonary embolism and pneumothorax in those randomized to gabapentin. The likelihood that these events were related to study medication administration was low. Patients were not able to correctly guess randomization status (χ 2 P =. 3 0 )
suggesting that blinding was successful.
Discussion
To our knowledge, we report the results of the first randomized trial of perioperative use of gabapentin with extensive postoperative longitudinal follow-up and patient contact totaling 19 511 telephone calls up to 2 years after surgery. Perioperative gabapentin, 1200 mg, administered preoperatively plus 600 mg every 8 hours continued for 72 hours after surgery did not affect time to pain cessation, the rate of pain resolution, or the proportion of patients with chronic pain at 6 months or 1 year following surgery. However, perioperative gabapentin demonstrated a modest effect in promoting postoperative opioid cessation. Based on these findings, perioperative gabapentin may promote opioid cessation and prevent the development of chronic opioid use after surgery. a There were no significant differences between the treatment groups. P Յ .002 was considered to indicate significance in these between-group comparisons.
b Percentages do not include patients with missing data.
c Scale range, 0 (no pain) to 10 (worst pain imaginable).
d Scale range, 0 to 26, with 0 to 3 indicating low risk.
e Scale range, 0 to 33, with 0 to 8 indicating low concern for social approval and 20 to 33 indicating high concern for social approval.
f Scale range, 30 to 120, with higher scores representing greater impulsiveness.
g Scale range, 17 to 85, with increasing scores representing more self-reported posttraumatic stress disorder symptoms.
h Scale range, 20 to 80, with higher scores representing increasing state anxiety (anxiety in response to a specific situation).
i Scale range, 20 to 80, with higher scores representing increasing trait anxiety (propensity to experience anxiety). Our clinical trial is consistent with research regarding the lack of efficacy of perioperative gabapentin in the context of acute pain and adds to the existing literature by extending these findings to postoperative pain resolution. The extensive longitudinal follow-up of this clinical trial allows us to characterize the continuum of pain and provides support for our null hypothesis that perioperative gabapentin has no effect on remote pain cessation.
Preoperative gabapentin is associated with significantly decreased levels of consciousness in a dose-dependent manner and longer postanesthesia care unit stays. 36, 37 Similarly, respiratory depression has been reported in patients receiving preoperative gabapentin, with greater risk noted in older patients and those receiving multimodal analgesia. 38, 39 In contrast, our study demonstrates a high rate of adverse events in both groups likely reflecting the postoperative state rather than a medication effect. Elderly patients and those with medical comorbidities excluded from this trial may experience more gabapentin-related adverse effects (somnolence, ataxia, sedation, dizziness 14, 22 ) and require reduced dosing.
Gabapentin significantly increased the rate of opioid cessation after hospital discharge. This finding resonates with earlier work suggesting that the determinants of the rate of opioid cessation are largely independent of the duration of pain and the determinants of time to pain resolution. 25, 26 Previous trials examining gabapentin's effect on opioid consumption have been limited to immediate postoperative use during hospital admission. 18, 19, 40 Significant dose reductions in the first 24 to 72 hours may not be clinically relevant as most patients continue to require opioids during this time. 40 Our study shows that 3 days of perioperative gabapentin may promote remote opioid cessation long after hospital discharge. Given the more significant and larger clinical effect noted in the per-protocol analysis, it is possible that extended postoperative gabapentin dosing would lead to even greater increases in postoperative opioid cessation. Although the results of the subgroup analyses presented in eAppendix 2 in Supplement 2 should be interpreted with caution, it appears that perioperative gabapentin may be more efficacious in promoting opioid cessation in the context of specific operations. Future studies should examine discrete surgical populations undergoing specific operations and determine the optimal dosing and timing of postoperative gabapentin to prevent chronic opioid use. Our findings mirror the opioid-sparing effects of gabapentin reported in other settings, as coadministration of gabapentin reduces opioid requirements. During opioid detoxification for addiction in patients without comorbid pain, concurrent gabapentin administration reduces illicit opioid use and decreases the intensity of withdrawal symptoms. [41] [42] [43] This effect may result from prevention of tolerance and opioidinduced withdrawal hyperalgesia. 44, 45 Similarly, animal studies and human case studies have reported mitigation of opioidinduced hyperalgesia and reduced opioid use, but the absence of standardized clinical trials precludes definitive conclusions.
46
Given legislation in several states limiting initial opioid prescribing for acute pain to 5 days, our study demonstrates that strict adaptation of this legislation into clinical practice may be detrimental to optimal acute postoperative pain management. A total of 340 of 410 (82.9%) patients in our mixed surgical cohort were still using opioids 5 days postoperatively, and 395 of 410 (96.3%) reported having continued pain at that time. Given the elevated risk of chronic opioid use for patients receiving opioids preoperatively and those initiating use of opioids after surgery, 25,47 gabapentin may be a valuable adjuvant to prevent the development of postoperative chronic opioid use.
Limitations
Our protocol tested whether adjunctive gabapentin improves current standard postoperative pain management. However, our permissive regimen may have increased between-patient variance as physicians prescribed different medications to different patients, and this may bias our outcomes toward the null.
Awareness of the potential utility of perioperative gabapentin and pregabalin for reducing immediate postoperative pain severity increased over the course of our study. This contributed directly to most of the protocol violations when patients received gabapentin or pregabalin outside of the study protocol. The mixture of active treatment into both treatment groups would be expected to bias our outcomes toward the null. In contrast, the absence of any effect for gabapentin on time to pain resolution was persistent and similar in the ITT and per protocol analyses, increasing confidence that the absence of such an effect is real.
Conclusions
In a mixed surgical cohort, perioperative gabapentin did not affect time to postoperative pain resolution. However, this regimen resulted in a modest increase in the rate of opioid cessation. Identifying gabapentin as an important adjuvant to promote definitive opioid cessation rather than merely reducing immediate postoperative opioid requirements has important and timely clinical implications in the context of the national epidemic of opioid overdose deaths and addiction. Future work examining the effect of extended postoperative gabapentin regimens and concurrent administration during opioid tapering in patients with chronic noncancer pain is warranted to further characterize the effects of gabapentin on opioid analgesic use (independent of effects on pain duration) and the mechanisms by which this medication promotes opioid cessation and prevents chronic opioid use. zero reported pain and five consecutive reports of zero opioid use. The endpoint is defined as the first 10 date of these reports. Patients will continue to receive phone calls until they, in addition to meeting the 11 endpoint as defined above, have stated they consider themselves recovered from surgery. 12 13 
Clinic Staff
105
The Principal Investigator will speak directly with all participating surgeons and pre-operative clinic staff 106 to inform them of the purpose of the research and the process for recruitment and patient referrals. 107
Referring physicians will be informed of the study design such that they are aware of what medication 108 their patients may be receiving, and the schedule of medication administration. 109 A form will be placed in the of their bed specifying that they are enrolled 110 in the trial and to contact the study team prior to giving Gabapentin. 111
Recruitment
112
Recruitment may take place via one of three methods: 113 
Clinical staff referral
Patient Enrollment
179
Eligible and interested patients:
180
Informed consent may be obtained in one of three ways: over the phone, at an already scheduled pre-181 operative visit, or at a newly scheduled lab visit. 182
Phone consent -the research team member will mail, fax, or email a .pdf of the approved 183 consent form to the patient. The patient will call the research team member once the consent 184 form is received, or the research coordinator or PI will call the patient to confirm receipt of the 185 consent document. The coordinator or PI will obtain informed consent from the participant, 186 who will bring the signed document with them on the day of surgery. Coordinator or PI will 187 verify signatures and sign the researcher signature line at that time. 188
In-person consent if the patient is returning to Stanford for an already scheduled pre-189 operative appointment, the coordinator or PI may meet the patient before or after this 190 
Patient Welcome Packet
206
Once patients are consented to participate, they will be given the START welcome packet, which will 207 include: pre-surgical assessment packet (see below), START information sheet, Flowchart for Patients, 208
Post-surgical medication reminders, a copy of their consent form, psychological services brochure, and a 209 business card for the study with study staff contact information. For patients who consented over the 210 phone, this packet will be mailed with the consent form to facilitate the consent process and so that the 211 patient may have these materials immediately once enrollment is complete. 212
Database Registration
213
Once a patient has enrolled in the trial, s/he will be entered into the SNAPL central database under 214
The research coordinator or assistant will register the patient in the Cancer Center Oncore Database 216 accessed online. A C C Oncore database within 30 days of 217 enrollment. Patients are registered under protocol VAR0054. Use the Oncore instruction guide found in 218 the START Admin folder on the server. 219
Pre-Surgical Assessment
220
Baseline Questionnaire Packet: 221 After enrollment, patients will complete a pre-surgical questionnaire packet. Pre-surgical assessment 222 questionnaires are documented below: 223
Pre-surgical Reminder Call
239
Study nurse will call the patient the night before surgery to confirm surgery time the following day, 240 review any eligibility information, and remind the patient to bring the baseline questionnaire packet. 241
Day of Surgery Assessment
242
Checklist CRF will be completed documenting day of surgery steps and post-surgical days1-3 steps. 243
Study staff will meet the patient prior to surgery to collect the questionnaire packet, collect the consent 244 form if not already obtained, confirm eligibility checklist has been completed up to 3 days prior to 245 surgery and verbally confirm with patient that no changes to health or medical status have occurred 246 since then, and begin randomization. 247
Tissue Collection
248
Patients who are undergoing spinal anesthesia as part of routine care will have a Cerebrospinal Fluid 249 sample obtained if they consent to do so. Prior to the injection of spinal anesthesia, a sample of CSF not 250 to exceed 20ml will be captured by the anesthesiologist placing the spinal anesthesia line. Sample will be 251 collected into an eppendorf tube and delivered to CTRU for processing according to the following 252 instructions: 253 6. CTRU will process and store the samples until we transfer them to HIMC for long-term storage 261 and analysis 262
Genetic sample 263 All patients will be asked to provide a saliva sample for genetic analysis through protocol 9435. Patients 264 will be consented separately and participation in START is not contingent on any participation in the 265 genetics study. Participation can occur at any time throughout the START trial after the baseline packet 266 has been received. 267
Randomization
268
Patients will be randomized after eligibility has been confirmed and checklist completed. Research 269 coordinator will deliver a prescription form signed by the PI to the OR pharmacy. 270
Randomization will be pre-generated using R " "TART R R 271 for detailed instructions on using the program. 272
Randomization will occur using blocked, stratified randomization by surgery and surgeon. 273
Randomization will be pre-generated onto logsheets to be provided to OR pharmacy; One log sheet will 274 be generated per combination of surgeon/surgery, with surgery to be color-coded for ease of 275 differentiation/use. When the pharmacist receives a prescription, s/he will find the appropriate log 276 based on surgery and surgeon for that patient and will fill in the next empty line of the log sheet, which 277 T 278 sticker on a START Randomization Card and indicate which medication was prescribed. This will be 279 placed in a sealed envelop " 280 envelopes weekly and store in the lab these will remain in the sealed envelopes until the end of the 281 study unless a safety issue requires un-blinding. Medication Logs will be maintained in a binder in the OR 282
Pharmacy. 283
Intervention
284
Patient receives medication from the study nurse, who picks it up from the OR pharmacy. Study team 285 member will document time at which patient received pre-operative medication. Normal standard of 286 care and medications will not be affected by study participation. If dose is given before the patient is in a 287 bed, the study nurse will stay with the patient for observation until s/he is in a bed. 288
Based on blinded randomization, patient receives: 289
Preoperative Medication: 290 4 capsules of 300mg Gabapentin (1200 mg total) OR 3 capsules of inactive placebo plus 1 capsule of 291 active placebo (0.5mg Lorazepam) 292
Post-operative Medication:
293 2 capsules of 300mg Gabapentin three times a day (6 total capsules, 1800mg total daily dose) OR 2 294 capsules of inactive placebo three times a day (6 total capsules) continued for 72 hours post-surgery (10 295 total doses/20 total capsules over the 72 hour period)Doses will be administered under the default EPIC 296 TID option of 0600, 1400, and 2200. Medication administration will start on the day of surgery at the 297 soonest timepoint (eg 1400 if surgery ends at 1200), or the next day if surgery ends past the tid 298 timepoint that day (eg 0600 the following day if surgery ends at 2300). Medication is stored in the 299 tower pixis. 300
If the patient is not assigned a bed by 4pm, study nurse will pick up the medication directly from the OR 301 pharmacy and deliver it to the floor once the patient is bedded for storage in the tower pixis. 302
If patients are discharged before the 72 hour period ends, they will be given the remainder of their 303 capsules to take at home. They will also be given a pill dispenser and instructions for taking the 304 medication. This will be dictated in a note in EPIC to the nurses, and patients will be instructed to ask 305 the nurse for the remainder of their study medication from their medication bin upon discharge. The 306 research team member will confirm this process with the patient and nurse. 307
Medication Adjustment for Side Effects
308
Participants who experience significant sedation, as assessed by a dizziness or sedation rating of 7 or 309 greater on the side effect assessment form, patient dosage will be reduced by half (1 capsule of 300mg  310 Gabapentin three times a day for a total dosage of 900mg daily, OR 1 capsule of inactive placebo three 311 times a day).
with instructions to the pharmacy to reduce the dose. Research team member will follow-up with a 313 page to the pharmacist on call. Research team member will pick up a new medication bottle label from 314 the pharmacy, and will remove the extra pills from the medication bottle for disposal. 315
Patients who have been discharged will be assessed over the phone and given instructions for dose 316 adjustment verbally. 317
If, at next assessment, patient dizziness or sedation remains at 7 or greater on side effect assessment 318 scale, medication administration is stopped. 319
Research team member will document whether dosage has been reduced or stopped on Medication 320
Administration CRF. 321 Patient will be asked by the research team member which medication they believe they received 343 throughout the study after the last dose is given, no later than the day following the last dose. If the 344 patient is discharged before assessment, it will be assessed at the first follow-up phone call after the last 345 dose is taken, and no later than the day after the last dose is taken. 346
Follow-up*
Discharge Date and Time
347
Study team member will verify information in EPIC and record it on the START Checklist. 348
Medical Chart Review
form. This will be done within 1 week after the date of surgery. 351
Post-operative Days 3 until Endpoint
352
Tracking of monthly and additional reports will occur via the tracking log. A patients surgery will be 353 entered into the log, which will populate all subsequent target dates and the log will be kept in the 354 patient binder. These will then be placed on the calendar for mailing. Date of mailing will be recorded, 355
and date the packet is received. 356
Daily Phone Calls: 357
After being discharged, the daily report of pain, medication use, and pain interference will be provided 358 over the phone to a member of the study team. Calls will begin in the morning and continue until early 359 evening. A missed call will be recorded as such. Calls will continue daily for 3 months, when the 360 frequency will reduce to weekly until the 6 month time-point, at which time calls will reduce to a 361 monthly basis. 362
Monthly Reports: 363 A more comprehensive report of drug use will occur on a monthly basis by mailing the participant a 364 questionnaire and stamped return-envelope. Alternatively and preferentially, patients will complete the 365 survey via an online REDCap Survey tool. Six months post-surgery patients will be mailed a more comprehensive questionnaire packet to assess 373 current mood, pain and functioning, PTSD symptomatology and quality of life. This applies to patients 374 still enrolled in the trial (Active patient) and those that have met endpoint (this 6-month post-375 enrollment assessment counts as the first of the up-to-once-every-6-months assessments) 376
One year post-surgery patients will complete an additional PTSD symptom inventory with the PCL. 377
Six months after opioid use stops, patients will be mailed an anonymous form to survey how opioids 378 were disposed of. 379 6 months and 2 years after endpoint is met, patients will be mailed a questionnaire packet including the 380 following: BDP, BPI, CDOQ, PCL, Euro-Qol, Daily Pain and opioid use questionnaire. 381
Patient Withdrawn or Study Completion 382
If patient is withdrawn from study, is lost to follow-up, or when the patient reaches the study endpoint, 383 a study staff member will document study completion by using Study Stop Point CRF. 384
Patient tracking log will be updated to reflect subsequent mailing dates no longer apply by crossing 385 them out, initialing, and providing the date. 386
Data Management
387
Data will be maintained on appropriate case report forms and participant questionnaires. Data will be 388 entered into an electronic format via the teleform system, by which forms are scanned into an 389 electronic format and stored as .txt or .csv files until imported into an electronic database. 390
Patient Identification Codes
391
Patients enrolled in the study will be labeled with a code as follows: 3 digit ID number First Initial Last 392
Initial. Example: 001XX 393
Data Storage
394
Binders will be stored in locked cabinets. 395
Screening & Eligibility Forms 396
Ok-To-Contact Sheets and phone will be maintained in a recruitment & screening binder in the relevant 397 section. A screening log will be maintained electronically documenting which patients were contacted 398 after giving permission on the ok-to-contact form or from a clinic staff member. The following 399 information will be recorded: the patient name, the date the patient was spoken with, the researcher 400 conducting the screening, the screening result (eligible, ineligible, declined to participate and reason), 401
whether the patient was enrolled, and any comments (eg when consent form packet was mailed to the 402 patient). 403
Eligibility checklist will be stored in the patient binder and a copy stored in the regulatory binder. 404
Case Report Forms 405
All original case report forms and patient questionnaires will be stored in 406 
Consent
Patient Adherence
421
Adherence to intervention will be recorded on the Medication Administration Record CRF. Patients have 422 been discharged prior to the 72-hour post-operative medication administration period will have 423 adherence measured by self-report. A study team member will meet with the patient prior to discharge 424 to instruct on how to take the post-operative medication dosages. Instructions will be repeated by 425 phone each day and patients will give a report, to the best of their ability, on the number of doses they 426 took and the timing. 427
Measures to promote adherence: An unanticipated problem is defined as unexpected (not in the consent form or package insert, or 457 unexpected in its severity or frequency), harmful, and related (probably caused by the research drug). 458 A major protocol deviation or violation includes any procedure that differs from the IRB approved 459 protocol that was intended to eliminate an immediate hazard to the participant, was harmful, or is 460 possible serious or continue non-compliance by a study staff member. 461
Serious adverse events, unanticipated problems, and major protocol deviations will be communicated 462 by the study staff to the PI immediately. All events will be communicated to the Cancer Center Trials 463
Office (CCTO) using the adverse event communication form within 5 days of the PI learning of the event. 464
A description of the event will be included. The CCTO will submit this information to the IRB. 465
All minor protocol deviations (those that do not meet the definition of a major deviation and do not 466 affect the interpretation or outcome of the study) will be reported to the CCTO annually. 467
Medication Ordering
468
Medication will be ordered through Los Altos Pharmacy and delivered to the Stanford Hospital research 469 pharmacy by a research team member. Gabapentin will be compounded in 300mg capsules. Matched 470 placebo capsules will be prepared by the compounding pharmacist; active placebo capsules will contain 471 0.5mg Lorazepam. Stanford Hospital research pharmacy will control dispensation and logging of 472 medication. 473
Trial Monitoring
474
Adverse Events, Serious Adverse Events, Unanticipated Problems, and Protocol Deviations will be 475 monitored on a continual basis and reported per information in the Adverse Events section. 476
Patient Adherence will be monitored as described in the relevant section. 477
The PI will hold regular staff meetings at least twice monthly to assess study team member 478 understanding of responsibilities as per the Education section. 479
Additional ongoing monitoring will occur as detailed below. Results will be recorded on START 480
Monitoring CRF. The PI will review and sign-off on the results and any suggested resolutions. 481
The first 10 patients will have case report forms and consent forms reviewed for accuracy and 482 completion immediately after enrollment and entry into the follow-up period. After the first ten 483 patients, case report forms and consent forms will be evaluated for completeness every 50 patients, or 484 every 3 months, whichever is sooner. A monitoring results report will be sent to the entire study team 485 and results will be discussed at the subsequent study team meeting. Ongoing issues with data 486 completion will be addressed with the individual team member and re-training may occur as necessary. 487
Data Safety and Monitoring Board
488
The Stanford Cancer Center will serve as the DSMB for the trial. Safety will be reviewed according to the 489 CCTO DSMB Standard Operating Procedures. 490
Case Report Form Completion
491
Missing data that is available through patient records such as EPIC will be recorded with a notation of 492 such. Data discrepancies will be compared to any source data such as EPIC and corrections made by 493 crossing out the original value, providing the correct value, dating, initialing, and providing a reason for 494 the correction. Missing data or data discrepancies that cannot be resolved by verifying source data will 495 be left as missing. 496
Consent Form Completion
497
Consent forms will be evaluated for completeness of all signatures, required initials, and dates. Any 498 missing signatures will be obtained by mailing the patient a copy of the consent form and requesting the 499 signature with the current date. Any missing PI signatures will be obtained and dated with the current 500 date. Patients with missing signatures who are unable, or unwilling, to provide missing signature will be 501 withdrawn from the study and data will not be used. 502
Electronic Data Verification
503
Electronic data is entered via the Stanford REDCap system. Patients enter responses directly into the 504 electronic system for monthly CDOQs, unless they specifically request a paper copy. Case Report Forms 505 are entered into REDCap by study staff, after they have completed instructional training and a mock-506 entry packet that is reviewed by the Research Manager, coordinator, or study monitor. 507
An additional 10% of data will be randomly verified by study staff prior to data analysis. Verification will 508 occur via visual inspection. Discrepancies will be noted, original source data checked, and the correct 509 value entered. All verified data will be noted with the reviewers initials and date. Corrections will be 510 noted with the date, initials, and reason for correction. Consistent errors will prompt a more 511 comprehensive review of the data at the PIs discretion. 512
Analysis
513
All randomized patients will be included in an intention to treat analysis. Patients with 100% compliance 514 will be tested in a per-protocol analysis. 515
Primary Endpoint
516
Time to pain resolution, defined as five consecutive days of reported zero out of ten average pain. 517
Secondary endpoints
518
Time to opioid cessation, defined by five consecutive days of zero reported opioid use. For patients 519 entering the trial already taking opioid medication, an additional endpoint will include time to return to 520 baseline levels of opioid use. 521
The proportion of patients continuing on chronic opioids at 6 month and 1 year. 522
The proportion of patients with continued pain at 6 months and 1 year. 523
Survival at 1 , 3, and 5 years. 524 PCL-C Scores at 6 and 12 months. 525
Background and Demographic Characteristics
526
Demographic and background information will be summarized with descriptive statistics (mean,  527 standard deviation, percentages, etc.) 528
Evaluation of Efficacy:
529
Primary and secondary endpoint will be analyzed using survival analysis or logistic regression stratified 530 by surgery type and surgeon as appropriate. Trial efficacy will be determined by the significance of 531 treatment assignment in the intention to treat analysis. 532
Methods for handling missing data and non-adherence to protocol: 533 Primary analysis will be intent to treat. Separate efficacy analysis on those with complete protocol 534 adherence will be done. Subjects dropping out will be censored at the last known data point. Competing 535 events such as a second surgery will be reasons for censoring at the time of the competing event. 536
Missing data will not be imputed. 537
Subgroup Analyses
538
Subgroup analysis will examine the treatment efficacy in high risk subgroups defined by the presence of 539 PTSD, Depression, High self report of addiction susceptibility. Preplanned subgroup analyses include: 540
Patients with PTSD symptoms at baseline as defined by answering yes to any question on primary care 541 PTSD screen, and patients with BDI scores greater than 13. Analysis will involve comparing single dose 542 versus continued dosing as dichotomous variable and continuous variable of total dose (since a 543 proportion will get only single dose secondary to side effects) 544 545
Interim Analyses
546
Planned interim analysis will be conducted every 100 events using the stopping rules outlined below and 547 the indicated P-values. 548 549
Note the p values here are one sided. So the p-value for efficacy on the final analysis will be an overall 550 p=0.043 551 For you specifically, how likely do you think it is that you will develop a new chronic pain problem after surgery? Not at all Unlikely Somewhat likely Very likely How sensitive are you to pain? More than average Average Less than average For you specifically, how likely do you think it is that you will develop an addiction problem from pain medication you take after surgery? Not at all Unlikely Somewhat likely Very likely Daily Pain and Opioid Use Questionnaire Please rate your pain from zero to ten where zero is no pain and ten is the worst pain you can imagine on the AVERAGE in the last 24 hours. 0 1 2 3 4 5 6 7 8 9 10 N o P a i n A s B a d A s P a i n Y o u C a n I m a g i n e
Please rate your pain from zero to ten where zero is no pain and ten is the worst pain you can imagine right NOW. Y o u C a n I m a g i n e
Please rate your pain from zero to ten where zero is no pain and ten is the worst pain you can imagine at its WORST in the last 24 hours. In the last 24 hours, has it been necessary for you to take any more pain medication than recommended?
___Yes ____NO
In general, over the last 24 hours which of these options best describes how often you have thought about your pain or pain medication:
Less than once per hour Several times an hour Every few minutes Constantly
